The Cystic Fibrosis Segment is Expected to Dominate the Global Lung Transplant Therapeutics Market with the Market Share of 93.52%

According to the world health organization (WHO), tobacco takes lives of more than 8 million people every year. Out of these, 7 million people are the direct tobacco consumers and 1.2 million people are just passive consumers. Tobacco smoking is associated with morbidity and mortality and as a result many people are estimated to die every year from the effects of second-hand smoke. Over 80% of the tobacco consumers put up in low and middle income economies.

Access Full Report @ https://www.databridgemarketresearch.com/ko/reports/global-lung-transplant-therapeutics-market

The global lung transplant therapeutics market is expected to reach USD 218.10 by 2029 from USD 152.73 million in 2021, growing at a lucrative CAGR of 4.8% in the forecast period of 2022 to 2029. Rising number of drug approval activities in the developed and developing economies is bolstering the growth of the market. Further, increasing expenditure pertaining to the number of research and development activities in combination with surging number of clinical trials is carving the way for the market to boom over the forecast period.

Increasing prevalence rate of chronic obstructive pulmonary disease (COPD) is expected to drive the market's growth rate

Rising incidence rate of chronic obstructive pulmonary disease (COPD) acts as a major market growth determinant for the lung transplant therapeutics market. According to the world health organization, 90% of the deaths as a result of chronic obstructive pulmonary disease (COPD) are witnessed in low and middle class economies. On the global level, chronic obstructive pulmonary disease (COPD) is the third leading cause of death causing more than 3.2 million deaths in 2019.

Report Scope and Market Segmentation

Segment Analysis:

The lung transplant therapeutics market is segmented on the basis of product, indication, type, technique, patient demographics, and end users.

• Based on product, the global lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products and others. In 2022, the immunosuppressant drugs segment is expected to dominate the global lung transplant therapeutics market with the market share of 93.12% due to the use of immunosuppressant drugs to avoid lung rejection and the availability in hospitals and retail stores.
• Based on type, the global lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the global lung transplant therapeutics market with the market share of 59.77% due to increased awareness regarding organ donation and registration.
• Based on indication, the global lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the global lung transplant therapeutics market with the market share of 93.52% due to the surge in the patient pool of cystic fibrosis patients.

Cystic fibrosis segment is expected to dominate the global lung transplant therapeutics market in 2022

Cystic fibrosis has become a common genetic disorder which affects the respiratory and digestive systems of the body. It is an inherited life threatening disorder the symptoms of which include shortness of breath, chronic cough and lung infection. Rising prevalence of cystic fibrosis is responsible for boosting up the growth rate of the market.  

• Based on technique, the global lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the global lung transplant therapeutics market with the market share of 89.08% due to the surge in lung transplantation procedures.
• Based on patient demographics, the global lung transplant therapeutics market is segmented into with adult, pediatric and geriatric. In 2022, the geriatric segment is expected to dominate the global lung transplant therapeutics market with the market share of 65.03% due to surge in health complications observed in the geriatric populace and the genetic makeup of the geriatric patients, which would determine the lung transplantation procedure.
• Based on end users, the global lung transplant therapeutics market is segmented into hospital, transplant centers, specialty centers, and others. In 2022, the hospital segment is expected to dominate the global lung transplant therapeutics market with the market share of 49.43% due to increased awareness regarding organ donation, registration, and chronic diseases.

Hospital dominates the end user segment of lung transplant therapeutics market

Growing number of hospitals and healthcare facilities especially in the developing economies is a positive sign for the market. Rising number of hospitalization rate in the lower and middle class economies is yet another factor acting as a market growth determinant. Rising public and private expenditure on the development of healthcare infrastructure is also act as a determinant. 

Major Players

Data Bridge Market Research recognizes the following companies as the major advanced wound care market players in advanced wound care market are Novartis AG (Switzerland), BioLife Solutions (US), Paragonix Technologies, Inc (US), Detraxi, Inc. (US), Dr. Franz Köhler Chemie GmbH (Gemrany), and Pfizer Inc. (US)

Market Development

• In July 2021, Astellas Pharma Inc., announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for PROGRAF (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients. Astellas Pharma Inc. received the "2021 Award for Excellence in Corporate Disclosure" from the Securities Analysts Association of Japan. This helped company in strengthening its position over the market, gaining more customer base.
• In September 2021, a clinical trial was conducted, “NOVEL Lung Trial Extension: Normothermic Ex Vivo Lung Perfusion (EVLP) as an Assessment of Extended/Marginal Donor Lungs”, to see if donor lungs that may not normally qualify for transplant can be further assessed and improved so they can be transplanted.
• In December 2020, a clinical trial was conducted, “A Phase 2B Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant Recipients with Respiratory Syncytial Virus (RSV)”, to evaluate a new medication that attempts to treat RSV infection in lung transplant recipients who have respiratory infection symptoms for less than seven days.
• In May 2021, FDA approved sotorasib (Lumakras) as the first treatment for NSCLC patients whose tumors have the KRAS G12C genetic mutation and who have received at least one prior systemic therapy. On May 28, 2021, the FDA allowed sped up endorsement to sotorasib (Lumakras, Amgen) for the therapy of grown-ups with non-small cell lung cancer (NSCLC) with a Kirsten rodent sarcoma proto-oncogene (KRAS) G12C transformation who have gotten something like one in earlier foundational treatment.
• FDA approved amivantamab-vmjw (Rybrevant) for adults with NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. On May 21, 2021, the FDA supported amivantamab as the primary treatment for grown-up patients with NSCLC who harbor EGFR exon 20 inclusion transformations. The administrative agency additionally gave the go-ahead to Guardant360 CDx, created by Guardant Health Inc., for use as a symptomatic for the medication.

Regional Analysis

Geographically, the countries covered in the lung transplant therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in advanced wound care market during the forecast period 2022 -2029

In 2022, North America dominated the lung transplant therapeutics market owing to the higher level of investments by U.S. manufacturers and increasing prevalence of COPD in U.S.  North America will continue to dominate the lung transplant therapeutics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new products in this region. Additionally, the increasing number of cases of chronic wounds and the rising geriatric population are expected to further enhance the market's growth rate in this region. 

Asia-Pacific is estimated to be the fastest growing region in advanced wound care market the forecast period 2022 -2029

Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development of medical facilities in emerging economies in this region. In addition to this, rising level of healthcare expenditure and increasing per-capita income are expected propel the market's growth rate in this region.

COVID-19 Impact Analysis

The outbreak of COVID-19 largely impacted the healthcare industry. The lung transplant therapeutics market was, however significantly affected by it.  Rising number of patients on daily basis suffering from respiratory diseases positively impacted the market. Also, rising number of healthcare facilities in this pandemic phase all around the globe boosted the market growth rate. However, the imposition of the lockdown and social distancing restrictions by the government put a halt on the transplant procedures and surgeries. The pandemic led to the utilization of resources towards meeting the demand arising out of COVID-19 emergencies. Stifling business growth, suspensions of new developments were also responsible in limiting the industry's expansion.

On the other hand, there has been a decline in COVID-19 patients worldwide, which will result in increased health care services. Moreover, the restrictions and measures are likely to relax, which will help market to witness a slight increment, as the manufacturers are focusing on various developments and innovations, market trends, and other expansion strategies.

For more detailed information about the lung transplant therapeutics market report, click here – https://www.databridgemarketresearch.com/ko/reports/global-lung-transplant-therapeutics-market